News
Kriya Medical Technologies secures manufacturing license for KRIVIDA Trivus Respi Panel RT-qPCR Kit
IMT News Desk
Kriya Medical Technologies secures manufacturing license for KRIVIDA Trivus Respi Panel RT-qPCR Kit
IMT News Desk
Krivida Trivus offers simultaneous detection of, RSV (Respiratory Syncytial Virus), Influenza Viruses and SARS-CoV-2 in a single swab sample
Kriya Medical Technologies has received its manufacturing license from the Central Drugs Standard Control Organization (CDSCO) for its product KRIVIDA Trivus Respi Panel RT-qPCR Kit, a first-of-its-kind kit that has the unique capability to simultaneously identify Respiratory Syncytial Virus (RSV), influenza viruses and SARS-CoV-2 in patients presenting with respiratory tract infections.
KRIVIDA Trivus Respi Panel RT-qPCR kit has been validated by ICMR at the National Institute of Virology, Pune, and the kit has shown 100 per cent specificity and 99.11 per cent sensitivity for the detection of all three viruses.
A key feature of this kit is its ability to detect RSV, a virus that primarily causes viral pneumonia in children under the age of five and contributes significantly to hospitalisations. Additionally, RSV is a common cause of lower respiratory tract diseases (LRTD) in older adults, potentially leading to life-threatening pneumonia and bronchiolitis. Hence, early detection of RSV is imperative for both infants and the elderly.
Dr Shanmugapriya, MD, R&D Head, Kriya Medical Technologies, said “12.9 per cent of infant deaths in India are caused by pneumonia. 29 per cent of infants with pneumonia are infected with Respiratory Syncytial Virus in India. The mortality rate of RSV infection in a healthy infant is 0.5 to 1.7 per cent and is as high as 60 per cent in immunocompromised infants. The rationale behind the design of the Krivida Trivus Multiplex RT PCR kit is grounded in the recognition of the fact that timely and accurate diagnosis of RSV is key for avoiding severe forms of pneumonia and death, and this helps in a significant reduction in the infant mortality rate. We decided to include Influenza detection, as Influenza (A and B) causes 29 per cent of pneumonia in infants and using a specific antiviral drug in the earliest phase of illness can reduce the burden of complications."
Anu Moturi, CEO and Founder, Kriya Medical Technologies, said, “In the wake of the upcoming flu season, the Krivida Trivus Respi Panel RT-qPCR Kit is timely and essential since it helps with accurate and rapid identification of the responsible pathogens, enabling healthcare providers to initiate appropriate treatments promptly, reducing the risk of complications and improving patient outcomes. It enables accurate identification of causative agents, enabling targeted and specific treatments resulting in an increased number of successful outcomes. Acquiring this license is yet another milestone and a step towards our vision of making good healthcare affordable and accessible to all. The Krivida Trivus Respi Panel RT-qPCR Kit is a testament to our commitment to innovation and addressing critical healthcare needs.
The kit seamlessly integrates with all available RT PCR instruments. This compatibility ensures that healthcare facilities can effortlessly incorporate the kit into their existing diagnostic infrastructure, optimising operational efficiency.
“We strongly feel that incorporating Krivida Trivus into the existing RT-PCR infrastructure in laboratories will undoubtedly enhance the capacity of labs to offer a broader range of value-added diagnostic services. It's a strategic move that aligns with our commitment to innovation and improved patient care. By simultaneously targeting three viral infections, as compared to running individual tests for each of these pathogens as currently available, the kit offers a 10X reduction in cumulative testing costs and 3X reduction in TAT,” Anu added.